Log In
Print
BCIQ
Print
Print this Print this
 

Arbaclofen ER (OS-440)

  Manage Alerts
Collapse Summary General Information
Company Osmotica Pharmaceutical Corp.
DescriptionArbaclofen extended-release tablets
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase III
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat patients with spasticity due to multiple sclerosis (MS)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today